The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System (DIPSS) risk categorization, which includes patient age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts. We...
Gespeichert in:
| Veröffentlicht in: | Blood 2012-03, Vol.119 (11), p.2657-2664 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2664 |
|---|---|
| container_issue | 11 |
| container_start_page | 2657 |
| container_title | Blood |
| container_volume | 119 |
| creator | Scott, Bart L. Gooley, Ted A. Sorror, Mohamed L. Rezvani, Andrew R. Linenberger, Michael L. Grim, Jonathan Sandmaier, Brenda M. Myerson, David Chauncey, Thomas R. Storb, Rainer Buxhofer-Ausch, Veronika Radich, Jerald P. Appelbaum, Frederick R. Deeg, H. Joachim |
| description | Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System (DIPSS) risk categorization, which includes patient age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts. We evaluated the prognostic usefulness of the DIPSS in 170 patients with myelofibrosis, 12 to 78 years of age (median, 51.5 years of age), who received hematopoietic cell transplantation (HCT) between 1990 and 2009 from related (n = 86) or unrelated donors (n = 84). By DIPSS, 21 patients had low-risk disease, 48 had intermediate-1, 50 had intermediate-2, and 51 had high-risk disease. Five-year incidence of relapse, relapse-free survival, overall survival, and nonrelapse mortality for all patients were 10%, 57%, 57%, and 34%, respectively. Among patients with DIPSS high-risk disease, the hazard ratio for post-HCT mortality was 4.11 (95% CI, 1.44-11.78; P = .008), and for nonrelapse mortality was 3.41 (95% CI, 1.15-10.09; P = .03) compared with low-risk patients. After a median follow-up of 5.9 years, the median survivals have not been reached for DIPSS risk groups low and intermediate-1, and were 7 and 2.5 years for intermediate-2 and high-risk patients, respectively. Thus, HCT was curative for a large proportion of patients with myelofibrosis, and post-HCT success was dependent on pre-HCT DIPSS classification. |
| doi_str_mv | 10.1182/blood-2011-08-372904 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3311279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120459518</els_id><sourcerecordid>928906823</sourcerecordid><originalsourceid>FETCH-LOGICAL-c558t-f8b8f246ba36517d67699178f8f77b7041aa9fe140921fba9a054df8b3153c9d3</originalsourceid><addsrcrecordid>eNp9UU1v1DAUtBCILoV_gJAviFPAH0lsX5BQW6BSJZBazpbjPO8aJXawvZX2xk-vt7u0cOH0Dm9m3rwZhF5T8p5SyT4MU4xjwwilDZENF0yR9gla0Y7JhhBGnqIVIaRvWiXoCXqR809CaMtZ9xydMMZ42wu5Qr9vNoDPd8HM3uLLUCAFU3wMZsLfU1yHmEtdXNuYfFjj610uMGMXE553MEXnhxSzz3hJMHpbMo7bYuMMGRtXtfAGZlPiEj3sZSxMEy7JhLxMJpT7Qy_RM2emDK-O8xT9-Hxxc_a1ufr25fLs01Vju06WxslBOtb2g-F9R8XYi14pKqSTTohBkJYaoxzQlihG3WCUIV07VhanHbdq5Kfo40F32Q4zjBZCNTLpJfnZpJ2Oxut_N8Fv9Dreas4pZUJVgXdHgRR_bSEXPfu8_8gEiNusFZOK9JLximwPSFvDyQncwxVK9L47fd-d3nenidSH7irtzd8OH0h_yqqAt0eAydZMrgZpfX7EdT0nlHePr0LN89ZD0tl6CLZWlMAWPUb_fyd3lsu80Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>928906823</pqid></control><display><type>article</type><title>The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Scott, Bart L. ; Gooley, Ted A. ; Sorror, Mohamed L. ; Rezvani, Andrew R. ; Linenberger, Michael L. ; Grim, Jonathan ; Sandmaier, Brenda M. ; Myerson, David ; Chauncey, Thomas R. ; Storb, Rainer ; Buxhofer-Ausch, Veronika ; Radich, Jerald P. ; Appelbaum, Frederick R. ; Deeg, H. Joachim</creator><creatorcontrib>Scott, Bart L. ; Gooley, Ted A. ; Sorror, Mohamed L. ; Rezvani, Andrew R. ; Linenberger, Michael L. ; Grim, Jonathan ; Sandmaier, Brenda M. ; Myerson, David ; Chauncey, Thomas R. ; Storb, Rainer ; Buxhofer-Ausch, Veronika ; Radich, Jerald P. ; Appelbaum, Frederick R. ; Deeg, H. Joachim</creatorcontrib><description>Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System (DIPSS) risk categorization, which includes patient age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts. We evaluated the prognostic usefulness of the DIPSS in 170 patients with myelofibrosis, 12 to 78 years of age (median, 51.5 years of age), who received hematopoietic cell transplantation (HCT) between 1990 and 2009 from related (n = 86) or unrelated donors (n = 84). By DIPSS, 21 patients had low-risk disease, 48 had intermediate-1, 50 had intermediate-2, and 51 had high-risk disease. Five-year incidence of relapse, relapse-free survival, overall survival, and nonrelapse mortality for all patients were 10%, 57%, 57%, and 34%, respectively. Among patients with DIPSS high-risk disease, the hazard ratio for post-HCT mortality was 4.11 (95% CI, 1.44-11.78; P = .008), and for nonrelapse mortality was 3.41 (95% CI, 1.15-10.09; P = .03) compared with low-risk patients. After a median follow-up of 5.9 years, the median survivals have not been reached for DIPSS risk groups low and intermediate-1, and were 7 and 2.5 years for intermediate-2 and high-risk patients, respectively. Thus, HCT was curative for a large proportion of patients with myelofibrosis, and post-HCT success was dependent on pre-HCT DIPSS classification.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2011-08-372904</identifier><identifier>PMID: 22234678</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Child ; Clinical Trials and Observations ; Female ; Hematologic and hematopoietic diseases ; Hemoglobins - analysis ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Models, Statistical ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - therapy ; Peripheral Blood Stem Cell Transplantation ; Primary Myelofibrosis - blood ; Primary Myelofibrosis - mortality ; Primary Myelofibrosis - therapy ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival Rate ; Transplantation ; Young Adult</subject><ispartof>Blood, 2012-03, Vol.119 (11), p.2657-2664</ispartof><rights>2012 American Society of Hematology</rights><rights>2015 INIST-CNRS</rights><rights>2012 by The American Society of Hematology 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c558t-f8b8f246ba36517d67699178f8f77b7041aa9fe140921fba9a054df8b3153c9d3</citedby><cites>FETCH-LOGICAL-c558t-f8b8f246ba36517d67699178f8f77b7041aa9fe140921fba9a054df8b3153c9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25630135$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22234678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, Bart L.</creatorcontrib><creatorcontrib>Gooley, Ted A.</creatorcontrib><creatorcontrib>Sorror, Mohamed L.</creatorcontrib><creatorcontrib>Rezvani, Andrew R.</creatorcontrib><creatorcontrib>Linenberger, Michael L.</creatorcontrib><creatorcontrib>Grim, Jonathan</creatorcontrib><creatorcontrib>Sandmaier, Brenda M.</creatorcontrib><creatorcontrib>Myerson, David</creatorcontrib><creatorcontrib>Chauncey, Thomas R.</creatorcontrib><creatorcontrib>Storb, Rainer</creatorcontrib><creatorcontrib>Buxhofer-Ausch, Veronika</creatorcontrib><creatorcontrib>Radich, Jerald P.</creatorcontrib><creatorcontrib>Appelbaum, Frederick R.</creatorcontrib><creatorcontrib>Deeg, H. Joachim</creatorcontrib><title>The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation</title><title>Blood</title><addtitle>Blood</addtitle><description>Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System (DIPSS) risk categorization, which includes patient age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts. We evaluated the prognostic usefulness of the DIPSS in 170 patients with myelofibrosis, 12 to 78 years of age (median, 51.5 years of age), who received hematopoietic cell transplantation (HCT) between 1990 and 2009 from related (n = 86) or unrelated donors (n = 84). By DIPSS, 21 patients had low-risk disease, 48 had intermediate-1, 50 had intermediate-2, and 51 had high-risk disease. Five-year incidence of relapse, relapse-free survival, overall survival, and nonrelapse mortality for all patients were 10%, 57%, 57%, and 34%, respectively. Among patients with DIPSS high-risk disease, the hazard ratio for post-HCT mortality was 4.11 (95% CI, 1.44-11.78; P = .008), and for nonrelapse mortality was 3.41 (95% CI, 1.15-10.09; P = .03) compared with low-risk patients. After a median follow-up of 5.9 years, the median survivals have not been reached for DIPSS risk groups low and intermediate-1, and were 7 and 2.5 years for intermediate-2 and high-risk patients, respectively. Thus, HCT was curative for a large proportion of patients with myelofibrosis, and post-HCT success was dependent on pre-HCT DIPSS classification.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Clinical Trials and Observations</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Peripheral Blood Stem Cell Transplantation</subject><subject>Primary Myelofibrosis - blood</subject><subject>Primary Myelofibrosis - mortality</subject><subject>Primary Myelofibrosis - therapy</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><subject>Transplantation</subject><subject>Young Adult</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAUtBCILoV_gJAviFPAH0lsX5BQW6BSJZBazpbjPO8aJXawvZX2xk-vt7u0cOH0Dm9m3rwZhF5T8p5SyT4MU4xjwwilDZENF0yR9gla0Y7JhhBGnqIVIaRvWiXoCXqR809CaMtZ9xydMMZ42wu5Qr9vNoDPd8HM3uLLUCAFU3wMZsLfU1yHmEtdXNuYfFjj610uMGMXE553MEXnhxSzz3hJMHpbMo7bYuMMGRtXtfAGZlPiEj3sZSxMEy7JhLxMJpT7Qy_RM2emDK-O8xT9-Hxxc_a1ufr25fLs01Vju06WxslBOtb2g-F9R8XYi14pKqSTTohBkJYaoxzQlihG3WCUIV07VhanHbdq5Kfo40F32Q4zjBZCNTLpJfnZpJ2Oxut_N8Fv9Dreas4pZUJVgXdHgRR_bSEXPfu8_8gEiNusFZOK9JLximwPSFvDyQncwxVK9L47fd-d3nenidSH7irtzd8OH0h_yqqAt0eAydZMrgZpfX7EdT0nlHePr0LN89ZD0tl6CLZWlMAWPUb_fyd3lsu80Q</recordid><startdate>20120315</startdate><enddate>20120315</enddate><creator>Scott, Bart L.</creator><creator>Gooley, Ted A.</creator><creator>Sorror, Mohamed L.</creator><creator>Rezvani, Andrew R.</creator><creator>Linenberger, Michael L.</creator><creator>Grim, Jonathan</creator><creator>Sandmaier, Brenda M.</creator><creator>Myerson, David</creator><creator>Chauncey, Thomas R.</creator><creator>Storb, Rainer</creator><creator>Buxhofer-Ausch, Veronika</creator><creator>Radich, Jerald P.</creator><creator>Appelbaum, Frederick R.</creator><creator>Deeg, H. Joachim</creator><general>Elsevier Inc</general><general>Americain Society of Hematology</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120315</creationdate><title>The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation</title><author>Scott, Bart L. ; Gooley, Ted A. ; Sorror, Mohamed L. ; Rezvani, Andrew R. ; Linenberger, Michael L. ; Grim, Jonathan ; Sandmaier, Brenda M. ; Myerson, David ; Chauncey, Thomas R. ; Storb, Rainer ; Buxhofer-Ausch, Veronika ; Radich, Jerald P. ; Appelbaum, Frederick R. ; Deeg, H. Joachim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c558t-f8b8f246ba36517d67699178f8f77b7041aa9fe140921fba9a054df8b3153c9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Clinical Trials and Observations</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Peripheral Blood Stem Cell Transplantation</topic><topic>Primary Myelofibrosis - blood</topic><topic>Primary Myelofibrosis - mortality</topic><topic>Primary Myelofibrosis - therapy</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><topic>Transplantation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, Bart L.</creatorcontrib><creatorcontrib>Gooley, Ted A.</creatorcontrib><creatorcontrib>Sorror, Mohamed L.</creatorcontrib><creatorcontrib>Rezvani, Andrew R.</creatorcontrib><creatorcontrib>Linenberger, Michael L.</creatorcontrib><creatorcontrib>Grim, Jonathan</creatorcontrib><creatorcontrib>Sandmaier, Brenda M.</creatorcontrib><creatorcontrib>Myerson, David</creatorcontrib><creatorcontrib>Chauncey, Thomas R.</creatorcontrib><creatorcontrib>Storb, Rainer</creatorcontrib><creatorcontrib>Buxhofer-Ausch, Veronika</creatorcontrib><creatorcontrib>Radich, Jerald P.</creatorcontrib><creatorcontrib>Appelbaum, Frederick R.</creatorcontrib><creatorcontrib>Deeg, H. Joachim</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, Bart L.</au><au>Gooley, Ted A.</au><au>Sorror, Mohamed L.</au><au>Rezvani, Andrew R.</au><au>Linenberger, Michael L.</au><au>Grim, Jonathan</au><au>Sandmaier, Brenda M.</au><au>Myerson, David</au><au>Chauncey, Thomas R.</au><au>Storb, Rainer</au><au>Buxhofer-Ausch, Veronika</au><au>Radich, Jerald P.</au><au>Appelbaum, Frederick R.</au><au>Deeg, H. Joachim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2012-03-15</date><risdate>2012</risdate><volume>119</volume><issue>11</issue><spage>2657</spage><epage>2664</epage><pages>2657-2664</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System (DIPSS) risk categorization, which includes patient age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts. We evaluated the prognostic usefulness of the DIPSS in 170 patients with myelofibrosis, 12 to 78 years of age (median, 51.5 years of age), who received hematopoietic cell transplantation (HCT) between 1990 and 2009 from related (n = 86) or unrelated donors (n = 84). By DIPSS, 21 patients had low-risk disease, 48 had intermediate-1, 50 had intermediate-2, and 51 had high-risk disease. Five-year incidence of relapse, relapse-free survival, overall survival, and nonrelapse mortality for all patients were 10%, 57%, 57%, and 34%, respectively. Among patients with DIPSS high-risk disease, the hazard ratio for post-HCT mortality was 4.11 (95% CI, 1.44-11.78; P = .008), and for nonrelapse mortality was 3.41 (95% CI, 1.15-10.09; P = .03) compared with low-risk patients. After a median follow-up of 5.9 years, the median survivals have not been reached for DIPSS risk groups low and intermediate-1, and were 7 and 2.5 years for intermediate-2 and high-risk patients, respectively. Thus, HCT was curative for a large proportion of patients with myelofibrosis, and post-HCT success was dependent on pre-HCT DIPSS classification.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>22234678</pmid><doi>10.1182/blood-2011-08-372904</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2012-03, Vol.119 (11), p.2657-2664 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3311279 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Biological and medical sciences Child Clinical Trials and Observations Female Hematologic and hematopoietic diseases Hemoglobins - analysis Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Models, Statistical Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Peripheral Blood Stem Cell Transplantation Primary Myelofibrosis - blood Primary Myelofibrosis - mortality Primary Myelofibrosis - therapy Prognosis Retrospective Studies Risk Factors Survival Rate Transplantation Young Adult |
| title | The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T18%3A32%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Dynamic%20International%20Prognostic%20Scoring%20System%20for%20myelofibrosis%20predicts%20outcomes%20after%20hematopoietic%20cell%20transplantation&rft.jtitle=Blood&rft.au=Scott,%20Bart%20L.&rft.date=2012-03-15&rft.volume=119&rft.issue=11&rft.spage=2657&rft.epage=2664&rft.pages=2657-2664&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2011-08-372904&rft_dat=%3Cproquest_pubme%3E928906823%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=928906823&rft_id=info:pmid/22234678&rft_els_id=S0006497120459518&rfr_iscdi=true |